Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma.

McMichael EL, Benner B, Atwal LS, Courtney NB, Mo X, Davis ME, Campbell AR, Duggan MC, Williams K, Martin K, Levine K, Olaverria Salavaggione GN, Noel T, Ganju A, Uppati S, Paul B, Olencki T, Teknos TN, Savvides P, Tridandapani S, Byrd JC, Caligiuri MA, Liu SV, Carson WE 3rd.

Clin Cancer Res. 2019 May 29. doi: 10.1158/1078-0432.CCR-18-2108. [Epub ahead of print]

PMID:
31142501
2.

Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro.

Benner B, Scarberry L, Suarez-Kelly LP, Duggan MC, Campbell AR, Smith E, Lapurga G, Jiang K, Butchar JP, Tridandapani S, Howard JH, Baiocchi RA, Mace TA, Carson WE 3rd.

J Immunother Cancer. 2019 May 28;7(1):140. doi: 10.1186/s40425-019-0622-0.

3.

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.

Duggan MC, Regan-Fendt K, Olaverria Salavaggione GN, Howard JH, Stiff AR, Sabella J, Latchana N, Markowitz J, Gru A, Tridandapani S, Eisfeld AK, de la Chapelle A, Carson WE.

Melanoma Res. 2019 May 20. doi: 10.1097/CMR.0000000000000623. [Epub ahead of print]

PMID:
31116161
4.

Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature.

Suarez-Kelly LP, Yu L, Kline D, Schneider EB, Agnese DM, Carson WE.

Hered Cancer Clin Pract. 2019 Mar 25;17:12. doi: 10.1186/s13053-019-0110-z. eCollection 2019.

5.

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. doi: 10.6004/jnccn.2019.0018.

PMID:
30959471
6.

Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function.

Mace TA, Ware MB, King SA, Loftus S, Farren MR, McMichael E, Scoville S, Geraghty C, Young G, Carson WE 3rd, Clinton SK, Lesinski GB.

Sci Rep. 2019 Mar 25;9(1):5068. doi: 10.1038/s41598-019-41687-z.

7.

Emerging roles of and therapeutic strategies targeting BRD4 in cancer.

White ME, Fenger JM, Carson WE 3rd.

Cell Immunol. 2019 Mar;337:48-53. doi: 10.1016/j.cellimm.2019.02.001. Epub 2019 Feb 4. Review.

8.

Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.

Regan-Fendt KE, Xu J, DiVincenzo M, Duggan MC, Shakya R, Na R, Carson WE 3rd, Payne PRO, Li F.

NPJ Syst Biol Appl. 2019 Feb 26;5:6. doi: 10.1038/s41540-019-0085-4. eCollection 2019.

9.

Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.

McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA, Awan FT, Woyach J, Carson WE 3rd, Butchar J, Tridandapani S, Hertlein E, Castro CE, Muthusamy N, Byrd JC.

Blood Adv. 2019 Feb 12;3(3):447-460. doi: 10.1182/bloodadvances.2018025684.

10.

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.

Suarez-Kelly LP, Levine KM, Olencki TE, Del Campo SEM, Streacker EA, Brooks TR, Karpa VI, Markowitz J, Bingman AK, Geyer SM, Kendra KL, Carson WE.

Cancer Immunol Immunother. 2019 Apr;68(4):619-629. doi: 10.1007/s00262-019-02308-w. Epub 2019 Feb 6. No abstract available.

11.

Effect of topical microporous polysaccharide hemospheres on the duration and amount of fluid drainage following mastectomy: a prospective randomized clinical trial.

Suarez-Kelly LP, Pasley WH, Clayton EJ, Povoski SP, Carson WE, Rudolph R.

BMC Cancer. 2019 Jan 23;19(1):99. doi: 10.1186/s12885-019-5293-1.

12.

Concurrent phyllodes tumor, eccrine carcinoma, and multinodular goiter 20 years after radiotherapy for Hodgkin lymphoma.

Quinn KM, Tozbikian G, Carson WE.

Clin Case Rep. 2018 Nov 6;6(12):2498-2503. doi: 10.1002/ccr3.1854. eCollection 2018 Dec.

13.

Unusual recurrence of breast cancer in a BRCA-variant patient after fat grafting.

Skendelas JP, Lee C, Mangino A, Carson WE 3rd.

Clin Case Rep. 2018 Oct 31;6(12):2457-2462. doi: 10.1002/ccr3.1861. eCollection 2018 Dec.

14.

Pilot randomized controlled trial of a symptom cluster intervention in advanced cancer.

Wells-Di Gregorio SM, Marks DR, DeCola J, Peng J, Probst D, Zaleta A, Benson D, Cohn DE, Lustberg M, Carson WE, Magalang U.

Psychooncology. 2019 Jan;28(1):76-84. doi: 10.1002/pon.4912. Epub 2018 Oct 30.

PMID:
30335211
15.

Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma.

Latchana N, DiVincenzo MJ, Regan K, Abrams Z, Zhang X, Jacob NK, Gru AA, Fadda P, Markowitz J, Howard JH, Carson WE 3rd.

J Surg Oncol. 2018 Sep;118(3):501-509. doi: 10.1002/jso.25163. Epub 2018 Aug 21.

PMID:
30132912
16.

Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma.

Olaverria Salavaggione GN, Duggan MC, Carson WE.

Melanoma Res. 2018 Oct;28(5):390-397. doi: 10.1097/CMR.0000000000000474.

PMID:
30020196
17.

Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.

Buteyn NJ, Fatehchand K, Santhanam R, Fang H, Dettorre GM, Gautam S, Harrington BK, Henderson SE, Merchand-Reyes G, Mo X, Benson DM, Carson WE 3rd, Vasu S, Byrd JC, Butchar JP, Tridandapani S.

Int Immunol. 2018 Jul 24;30(8):375-383. doi: 10.1093/intimm/dxy040.

18.

Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors.

Lai X, Stiff A, Duggan M, Wesolowski R, Carson WE 3rd, Friedman A.

Proc Natl Acad Sci U S A. 2018 May 22;115(21):5534-5539. doi: 10.1073/pnas.1721559115. Epub 2018 May 7.

19.

Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.

Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, London CA, Xu T, Carson WE 3rd.

Cancer Immunol Res. 2018 Jun;6(6):671-684. doi: 10.1158/2326-6066.CIR-17-0343. Epub 2018 Apr 5.

20.

Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.

Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE.

Sci Rep. 2018 Mar 6;8(1):4203. doi: 10.1038/s41598-018-21306-z.

21.

Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity.

Suarez-Kelly LP, Akagi K, Reeser JW, Samorodnitsky E, Reeder M, Smith A, Roychowdhury S, Symer DE, Carson WE.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002352. doi: 10.1101/mcs.a002352. Print 2018 Apr. Review.

22.

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.

Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, Kendra K, Campbell A, Gautam S, Abood D, Landi I, Hsu V, Duggan M, Wesolowski R, Old M, Howard JH, Yu L, Stasik N, Olencki T, Muthusamy N, Tridandapani S, Byrd JC, Caligiuri M, Carson WE.

Clin Cancer Res. 2018 Apr 15;24(8):1891-1904. doi: 10.1158/1078-0432.CCR-17-0691. Epub 2018 Jan 23.

23.

Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies.

Xu J, Regan-Fendt K, Deng S, Carson WE, Payne PRO, Li F.

Pac Symp Biocomput. 2018;23:92-103.

24.

Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.

Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE.

Sci Rep. 2017 Nov 13;7(1):15424. doi: 10.1038/s41598-017-14970-0. Erratum in: Sci Rep. 2018 Mar 6;8(1):4203.

25.

Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.

Duggan MC, Stiff AR, Bainazar M, Regan K, Olaverria Salavaggione GN, Maharry S, Blachly JS, Krischak M, Walker CJ, Latchana N, Tridandapani S, de la Chapelle A, Eisfeld AK, Carson WE 3rd.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9629-9634. doi: 10.1073/pnas.1704371114. Epub 2017 Aug 21.

26.

MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions.

Campbell AR, Duggan MC, Suarez-Kelly LP, Bhave N, Opheim KS, McMichael EL, Trikha P, Parihar R, Luedke E, Lewis A, Yung B, Lee R, Raulet D, Tridandapani S, Groh V, Yu L, Yildiz V, Byrd JC, Caligiuri MA, Carson WE 3rd.

Cancer Immunol Res. 2017 Sep;5(9):778-789. doi: 10.1158/2326-6066.CIR-16-0005. Epub 2017 Jul 19.

27.

Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.

Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson WE 3rd.

Cancer Immunol Immunother. 2017 Nov;66(11):1437-1447. doi: 10.1007/s00262-017-2038-3. Epub 2017 Jul 7.

28.

Novel rodent model of breast cancer survival with persistent anxiety-like behavior and inflammation.

Pyter LM, Suarez-Kelly LP, Carson WE 3rd, Kaur J, Bellisario J, Bever SR.

Behav Brain Res. 2017 Jul 14;330:108-117. doi: 10.1016/j.bbr.2017.05.011. Epub 2017 May 4.

29.

Plasma MicroRNA Levels Following Resection of Metastatic Melanoma.

Latchana N, Abrams ZB, Howard JH, Regan K, Jacob N, Fadda P, Terando A, Markowitz J, Agnese D, Payne P, Carson WE 3rd.

Bioinform Biol Insights. 2017 Feb 23;11:1177932217694837. doi: 10.1177/1177932217694837. eCollection 2017.

30.

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T.

J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):359.

PMID:
28463630
31.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM.

J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.

32.

Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy.

Suarez-Kelly LP, Campbell AR, Rampersaud IV, Bumb A, Wang MS, Butchar JP, Tridandapani S, Yu L, Rampersaud AA, Carson WE 3rd.

Nanomedicine. 2017 Apr;13(3):909-920. doi: 10.1016/j.nano.2016.12.005. Epub 2016 Dec 18.

33.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

34.
35.

Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?

Alfano CM, Peng J, Andridge RR, Lindgren ME, Povoski SP, Lipari AM, Agnese DM, Farrar WB, Yee LD, Carson WE 3rd, Kiecolt-Glaser JK.

J Clin Oncol. 2017 Jan 10;35(2):149-156. Epub 2016 Nov 28.

36.

The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.

Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Noel TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, Karpa V, Zhang X, Carson WE 3rd.

Oncotarget. 2016 Dec 6;7(49):81172-81186. doi: 10.18632/oncotarget.12791.

37.

Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.

Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM Jr, Blachly JS, Carson WE 3rd, Byrd JC, Butchar JP, Tridandapani S.

J Biol Chem. 2016 Dec 2;291(49):25656-25666. Epub 2016 Oct 25.

38.

MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches.

Markowitz J, Abrams Z, Jacob NK, Zhang X, Hassani JN, Latchana N, Wei L, Regan KE, Brooks TR, Uppati SR, Levine KM, Bekaii-Saab T, Kendra KL, Lesinski GB, Howard JH, Olencki T, Payne PR, Carson WE 3rd.

Onco Targets Ther. 2016 Sep 29;9:5931-5941. eCollection 2016.

39.

Global microRNA profiling for diagnostic appraisal of melanocytic Spitz tumors.

Latchana N, Regan K, Howard JH, Aldrink JH, Ranalli MA, Peters SB, Zhang X, Gru A, Payne PRO, Suarez-Kelly LP, Carson WE 3rd.

J Surg Res. 2016 Oct;205(2):350-358. doi: 10.1016/j.jss.2016.06.085. Epub 2016 Jul 4.

40.

MicroRNA dysregulation in melanoma.

Latchana N, Ganju A, Howard JH, Carson WE 3rd.

Surg Oncol. 2016 Sep;25(3):184-9. doi: 10.1016/j.suronc.2016.05.017. Epub 2016 May 20. Review.

PMID:
27566021
41.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Aug;14(8):945-58.

PMID:
27496110
42.

Classification of Indeterminate Melanocytic Lesions by MicroRNA Profiling.

Latchana N, Del Campo SE, Grignol VP, Clark JR, Albert SP, Zhang J, Wei L, Aldrink JH, Nicol KK, Ranalli MA, Peters SB, Gru A, Trihka P, Payne PR, Howard JH, Carson WE 3rd.

Ann Surg Oncol. 2017 Feb;24(2):347-354. doi: 10.1245/s10434-016-5476-9. Epub 2016 Jul 28.

PMID:
27469124
43.

A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.

Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, Grever M, Carson WE, Otterson GA.

Mol Cancer Ther. 2016 Sep;15(9):2244-50. doi: 10.1158/1535-7163.MCT-15-0879. Epub 2016 Jul 25.

44.

IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.

McMichael EL, Jaime-Ramirez AC, Guenterberg KD, Luedke E, Atwal LS, Campbell AR, Hu Z, Tatum AS, Kondadasula SV, Mo X, Tridandapani S, Bloomston M, Ellison EC, Williams TM, Bekaii-Saab T, Carson WE 3rd.

Clin Cancer Res. 2017 Jan 15;23(2):489-502. doi: 10.1158/1078-0432.CCR-16-0004. Epub 2016 Jul 19.

45.

Trajectories of Stress, Depressive Symptoms, and Immunity in Cancer Survivors: Diagnosis to 5 Years.

Andersen BL, Goyal NG, Westbrook TD, Bishop B, Carson WE 3rd.

Clin Cancer Res. 2017 Jan 1;23(1):52-61. doi: 10.1158/1078-0432.CCR-16-0574. Epub 2016 Jul 12.

46.

A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.

Liu JQ, Talebian F, Wu L, Liu Z, Li MS, Wu L, Zhu J, Markowitz J, Carson WE 3rd, Basu S, Bai XF.

J Immunol. 2016 Aug 15;197(4):1489-97. doi: 10.4049/jimmunol.1600052. Epub 2016 Jul 6.

47.

NKp80 Defines a Critical Step during Human Natural Killer Cell Development.

Freud AG, Keller KA, Scoville SD, Mundy-Bosse BL, Cheng S, Youssef Y, Hughes T, Zhang X, Mo X, Porcu P, Baiocchi RA, Yu J, Carson WE 3rd, Caligiuri MA.

Cell Rep. 2016 Jul 12;16(2):379-391. doi: 10.1016/j.celrep.2016.05.095. Epub 2016 Jun 30.

48.

A Progenitor Cell Expressing Transcription Factor RORγt Generates All Human Innate Lymphoid Cell Subsets.

Scoville SD, Mundy-Bosse BL, Zhang MH, Chen L, Zhang X, Keller KA, Hughes T, Chen L, Cheng S, Bergin SM, Mao HC, McClory S, Yu J, Carson WE 3rd, Caligiuri MA, Freud AG.

Immunity. 2016 May 17;44(5):1140-50. doi: 10.1016/j.immuni.2016.04.007. Epub 2016 May 10.

49.

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Apr;14(4):450-73.

PMID:
27059193
50.

Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.

Skinner CC, McMichael EL, Jaime-Ramirez AC, Abrams ZB, Lee RJ, Carson WE 3rd.

Melanoma Res. 2016 Aug;26(4):329-37. doi: 10.1097/CMR.0000000000000258.

Supplemental Content

Loading ...
Support Center